Fw: Update on HOT II Trial - Last call for volunteers

[Guest guest]

Update on HOT II Trial - Last call for volunteers

Update on HOT II Trial – Last call for volunteers

Following a further extension of the accrual period for HOT II, I am pleased to let you know that we have consented 75% of our target sample size. Treatment is delivered in Cardiff, Chichester, Great Yarmouth, Hull, London (Leytonstone and St 's Wood), Plymouth, Poole and Rugby. Assessments are carried out in London with the option of postal consent for patients unable to make more than one journey.

Due to a 3 months run-in period, accrual needs to finish at the end of March 2012 in order for all volunteers to be treated by the end of the year. Although we have a list of patients in work-up for the study, we are still looking for 5-10 additional volunteers who may be interested to take part. We would therefore be grateful if you could let us know of any potentially suitable volunteers amongst your patients AS SOON AS POSSIBLE.

For further information or to refer a patient, please see below.

Thank you for your help.

Kind regardsGrace

Grace SharpHOT II Trial Coordinator

HOT II summary and contact details

HOT II is a randomised double-blind controlled phase III trial of hyperbaric oxygen in patients suffering long-term adverse effects of radiotherapy (RT) for pelvic cancer, funded by Cancer Research UK and the Department of Health (ISRCTN 86894066).

Chief & Principal Investigators: Dr Jervoise Andreyev, Consultant Gastroenterologist in Pelvic Radiation Disease Prof Yarnold, Consultant Clinical Oncologist Assessments for the trial are undertaken at the Royal Marsden Hospital.

Treatment is delivered at participating hyperbaric medicine centres in Cardiff, Chichester, Great Yarmouth, Hull, London (Leytonstone and St 's Wood), Plymouth, Poole and Rugby.

If you have patients with chronic RT-induced symptoms in your clinic who fit the following main inclusion criteria:- Past history of cancer of the rectum, prostate, testis, bladder, uterine cervix, uterine corpus or ovary- Bowel symptoms due to RT; diarrhoea, faecal incontinence, bleeding etc- Radiotherapy at least 12 months ago

please ask them to contact me, or forward me their contact details. I will send them a copy of the patient information sheet and establish eligibility. For further information, please seehttp://www.royalmarsden.nhs.uk/RMH/healthcare/research/hot-ii.htm or contact me directly at the address below.

Many thanks.

Grace SharpHOT II Trial CoordinatorProfessor Yarnold's OfficeRoyal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PTTel: 0, Fax: 0, Email: grace.sharp@...

The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.